http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#Head
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#assertion
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#provenance
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#pubinfo
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#assertion
http://purl.obolibrary.org/obo/MONDO_0005052
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/MONDO_0005052
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://go.drugbank.com/drugs/DB00904
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
http://www.w3.org/2000/01/rdf-schema#label
Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a major cost to healthcare services. IBS-D patients represent about one-third of the IBS population and are currently treated with antispasmodics, loperamide, bile acid sequestrants and antidepressants. Alosetron and rifaximin are also available in USA, ramosetron in Japan, Korea and Thailand and ondansetron as an off-label treatment.
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
https://w3id.org/biolink/vocab/has_population_context
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#cohort
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
https://w3id.org/biolink/vocab/publications
https://pubmed.ncbi.nlm.nih.gov/28276811/
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/OffLabelIndication
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#cohort
http://www.w3.org/2000/01/rdf-schema#label
Adults
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#cohort
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Cohort
https://go.drugbank.com/drugs/DB00904
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#provenance
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-7641-6446
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#pubinfo
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig
http://purl.org/nanopub/x/hasSignature
L7B3xksOrZtTwhr+neU351oQTkKxdQ8d6a7uB9vlY5FxCWACAqmvtx4gDCK8OTP1qgKrtMHNis/p13yNWgfZjSb2q7c9F/CjxDznQctKGkNa3ny8089AEfMTBl7XUhx/OwnzPrsPBm9ZVzyQZDuz8mJZ+eLSRgXl8+tIIr2JWRc=
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
http://purl.org/dc/terms/created
2021-05-28T17:40:31.342+02:00
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-7641-6446
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs